OXFORD, Miss., Dec. 11, 2017 /PRNewswire/ -- Cloaked Therapeutics and Romulus Titan have formed a joint venture, Cloaked Therapeutics Development, LLC, to facilitate development of the TumorSelect® cancer chemotherapy platform.
Chemotherapeutic agents can be very toxic and are typically dosed until the damage done to healthy tissues reaches an unacceptable level. TumorSelect® technology is designed to direct more of the cancer drug into the tumor and less into healthy tissue which should greatly reduce toxic side effects to the patient but retain or even enhance the anticancer efficacy of the therapy.
TumorSelect® technology combines proprietary prodrugs of clinically proven therapies (such as taxanes), nanotechnology, and knowledge of human physiology. Tumors have a voracious appetite for cholesterol which facilitates tumor growth and fuels their proliferation. TumorSelect® has taken advantage of this need to create a stealth delivery system that disguises and delivers anticancer drugs with the assistance of both the human body and the tumor cell. Propriety prodrugs are assembled within nanoparticulates that carry them to tumor tissues where they are taken up and transformed rapidly into active drug that kills the cancer cells. This three-prong approach delivers the anticancer drug selectively to the tumors and thereby avoids or reduces the severe side effect toxicities associated with current cancer chemotherapy.
The TumorSelect® technology promises to improve patient quality of life, patient retention in treatment regimes, and lead to more rapid patient recovery post treatment, as well as greater efficacy.
About Cloaked Therapeutics:
Cloaked Therapeutics is a pre-clinical stage pharmaceutical company focused on developing novel anticancer therapies.
SOURCE Cloaked Therapeutics, LLC